首页> 外文期刊>Expert opinion on biological therapy >Economical aspect of biological therapy in inflammatory conditions in Hungary.
【24h】

Economical aspect of biological therapy in inflammatory conditions in Hungary.

机译:匈牙利炎症性疾病生物治疗的经济方面。

获取原文
获取原文并翻译 | 示例
       

摘要

INTRODUCTION: There has been a burst in the use of biological therapies in the past decade resulting in increasing costs. In 2006 - 2010 the following biological agents were available in Hungary: adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, and ustekinumab. All biological agents except rituximab were first line therapies; rituximab was a second line option in rheumatoid arthritis. AREAS COVERED: Data of the financing system related to health care services from the data warehouse of the Hungarian National Health Insurance Fund were in inflammatory conditions. Our analysis showed a constant increase in number of patients and overall cost of biological therapy as well as annual cost of biological agents. Distribution of first choice of biological therapy was compared in different diseases. Time from diagnosis to start of biological therapy showed relatively high deviations. EXPERT OPINION: In order to achieve both health benefit and cost-effectiveness it is crucial that biological therapy is initiated early enough in the course of the disease, after the failure of non-biological therapies. Health authorities in close collaboration with clinical decision-makers should ensure that early detection of the disease and early initiation of appropriate therapies-including non-biological and biological therapies-are carried out in the health care systems.
机译:简介:在过去的十年中,生物疗法的使用激增,导致成本增加。在2006年至2010年期间,匈牙利有以下生物制剂:阿达木单抗,西妥珠单抗,依那西普,戈利木单抗,英夫利昔单抗,利妥昔单抗,托珠单抗和乌斯他单抗。除利妥昔单抗外,所有生物制剂均为一线治疗;利妥昔单抗是类风湿关节炎的二线治疗选择。覆盖的区域:匈牙利国家健康保险基金数据仓库中与医疗服务相关的融资系统数据处于炎症状态。我们的分析表明,患者人数和生物治疗的总成本以及生物制剂的年成本不断增加。比较了不同疾病中首选生物疗法的分布。从诊断到开始生物治疗的时间显示出较高的偏差。专家意见:为了实现健康和成本效益,非生物疗法失败后,在疾病过程中尽早开始生物疗法至关重要。卫生当局应与临床决策者密切合作,确保在卫生保健系统中及早发现疾病并及早启动适当的疗法,包括非生物和生物疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号